Oncologic outcomes of patients with Merkel Cell Carcinoma (MCC): A multi-institutional cohort study - 12/04/21
Abstract |
Background |
Merkel cell carcinoma (MCC) is a rare cutaneous neuroendocrine tumor that primarily affects elderly patients. Despite aggressive treatment, overall survival (OS) remains low.
Methods |
This study is a multi-institutional, retrospective review of 102 patients with MCC. We evaluated OS, disease-specific survival (DSS), and risk factors for recurrence.
Results |
Median age of patients was 71.46% of patients recurred. Patients with stage I disease had median 5-year OS of 59.3%, compared to 68.1% DSS. For stage III, median 5-year OS was 46.0% vs 58.2% DSS. Disease stage and advanced age were risk factors for recurrence and decreased OS. Immunocompromised status and disease stage were the strongest predictors of DSS.
Conclusions |
DSS is significantly better than OS for patients with MCC. Many elderly patients with newly diagnosed MCC have low remaining life expectancy, regardless of their MCC diagnosis. Patient age and overall health status should be considered to personalize care plans for patients with MCC.
Le texte complet de cet article est disponible en PDF.Highlights |
• | Merkel cell carcinoma (MCC) is a disease of the elderly, with median age at diagnosis of 71 years. |
• | Disease-specific survival (DSS) is much better than overall survival (OS). |
• | Median DSS for stage III disease was 90.8 months compared to 24.1 month median OS. |
• | Patient immunocompromise and disease stage are the strongest predictors of DSS. |
• | Treatment of MCC must be personalized based on patient age and overall health status. |
Keywords : Merkel cell carcinoma, Neuroendocrine tumors, Disease-specific survival
Abbreviations : IQR, NED
Plan
Vol 221 - N° 4
P. 844-849 - avril 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?